{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:02:24Z","timestamp":1770843744089,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Taishan Scholar Program of Shandong Province","award":["Tsqn202103198"],"award-info":[{"award-number":["Tsqn202103198"]}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2024MH305"],"award-info":[{"award-number":["ZR2024MH305"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Yantai Scientific and Technological Innovation Development Program","award":["2024YT06000818"],"award-info":[{"award-number":["2024YT06000818"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04196-8","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T02:25:16Z","timestamp":1768616716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From mechanisms to therapy: the role of tertiary lymphoid structures in bladder cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Jinshan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo AB, Ballman KV, Sonpavde G, et al. Adjuvant pembrolizumab versus observation in Muscle-Invasive urothelial carcinoma. N Engl J Med. 2025;392:45\u201355.","journal-title":"N Engl J Med"},{"key":"4196_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4196_CR3","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74:784\u201395.","journal-title":"Eur Urol"},{"key":"4196_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234\u201341.","journal-title":"Eur Urol"},{"key":"4196_CR5","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404\u201323.","journal-title":"CA Cancer J Clin"},{"key":"4196_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4111\/icu.2018.59.5.285","volume":"59","author":"HS Kim","year":"2018","unstructured":"Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinoma. Investig Clin Urol. 2018;59:285\u201396.","journal-title":"Investig Clin Urol"},{"key":"4196_CR7","doi-asserted-by":"crossref","unstructured":"Yajima S, Masuda H. Immune checkpoint inhibitors and Antibody-Drug conjugates in urothelial carcinoma: current landscape and future directions. Cancers (Basel). 2025;17:1594.","DOI":"10.3390\/cancers17091594"},{"key":"4196_CR8","doi-asserted-by":"publisher","first-page":"1275378","DOI":"10.3389\/fimmu.2023.1275378","volume":"14","author":"A Vaccaro","year":"2023","unstructured":"Vaccaro A, van de Walle T, Ramachandran M, et al. Of mice and lymphoid aggregates: modeling tertiary lymphoid structures in cancer. Front Immunol. 2023;14:1275378.","journal-title":"Front Immunol"},{"key":"4196_CR9","doi-asserted-by":"publisher","first-page":"1413067","DOI":"10.3389\/fimmu.2024.1413067","volume":"15","author":"X Bao","year":"2024","unstructured":"Bao X, Lin X, Xie M, et al. Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy. Front Immunol. 2024;15:1413067.","journal-title":"Front Immunol"},{"key":"4196_CR10","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.tice.2023.102288","volume":"86","author":"D Ribatti","year":"2024","unstructured":"Ribatti D. Tertiary lymphoid structures, a historical reappraisal. Tissue Cell. 2024;86:102288.","journal-title":"Tissue Cell"},{"key":"4196_CR11","doi-asserted-by":"publisher","first-page":"115572","DOI":"10.1016\/j.ejca.2025.115572","volume":"225","author":"R Vion","year":"2025","unstructured":"Vion R, Roulleaux-Dugage M, Flippot R, et al. Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint Blockade efficacy. Eur J Cancer. 2025;225:115572.","journal-title":"Eur J Cancer"},{"key":"4196_CR12","doi-asserted-by":"publisher","first-page":"113652","DOI":"10.1016\/j.yexcr.2023.113652","volume":"429","author":"LM Tseng","year":"2023","unstructured":"Tseng LM, Lau KY, Chen JL, et al. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model. Exp Cell Res. 2023;429:113652.","journal-title":"Exp Cell Res"},{"key":"4196_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","volume":"38","author":"A Kaczmarek","year":"2013","unstructured":"Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:209\u201323.","journal-title":"Immunity"},{"key":"4196_CR14","doi-asserted-by":"crossref","unstructured":"Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and damps: what, when, and how? BioFactors. 2013;39:355\u201367.","DOI":"10.1002\/biof.1125"},{"key":"4196_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s12192-013-0422-2","volume":"18","author":"D D\u2019Eliseo","year":"2013","unstructured":"D\u2019Eliseo D, Manzi L, Velotti F. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of Immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones. 2013;18:801\u20138.","journal-title":"Cell Stress Chaperones"},{"key":"4196_CR16","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.3389\/fimmu.2019.02938","volume":"10","author":"S Luo","year":"2019","unstructured":"Luo S, Zhu R, Yu T, et al. Chronic inflammation: A common promoter in tertiary lymphoid organ neogenesis. Front Immunol. 2019;10:2938.","journal-title":"Front Immunol"},{"key":"4196_CR17","doi-asserted-by":"publisher","first-page":"424","DOI":"10.4049\/jimmunol.169.1.424","volume":"169","author":"SA Luther","year":"2002","unstructured":"Luther SA, Bidgol A, Hargreaves DC, et al. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol. 2002;169:424\u201333.","journal-title":"J Immunol"},{"key":"4196_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","volume":"638","author":"M Amisaki","year":"2025","unstructured":"Amisaki M, Zebboudj A, Yano H, et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature. 2025;638:1076\u201384.","journal-title":"Nature"},{"key":"4196_CR19","doi-asserted-by":"publisher","first-page":"e70045","DOI":"10.1111\/imr.70045","volume":"332","author":"M Zuo","year":"2025","unstructured":"Zuo M, Wang AA, Gommerman JL. Follicle on the roof: tertiary lymphoid structures in central nervous system autoimmunity. Immunol Rev. 2025;332:e70045.","journal-title":"Immunol Rev"},{"key":"4196_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s42003-022-03344-6","volume":"5","author":"S Nayar","year":"2022","unstructured":"Nayar S, Pontarini E, Campos J, et al. Immunofibroblasts regulate LT\u03b13 expression in tertiary lymphoid structures in a pathway dependent on ICOS\/ICOSL interaction. Commun Biol. 2022;5:413.","journal-title":"Commun Biol"},{"key":"4196_CR21","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1111\/j.1600-6143.2012.04090.x","volume":"12","author":"Y Nakayama","year":"2012","unstructured":"Nakayama Y, Bromberg JS. Lymphotoxin-beta receptor Blockade induces inflammation and fibrosis in tolerized cardiac allografts. Am J Transpl. 2012;12:2322\u201334.","journal-title":"Am J Transpl"},{"key":"4196_CR22","doi-asserted-by":"publisher","first-page":"1063711","DOI":"10.3389\/fimmu.2022.1063711","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Wu S. Tertiary lymphoid structures are critical for cancer prognosis and therapeutic response. Front Immunol. 2022;13:1063711.","journal-title":"Front Immunol"},{"key":"4196_CR23","doi-asserted-by":"publisher","first-page":"661516","DOI":"10.3389\/fmolb.2021.661516","volume":"8","author":"R Mustapha","year":"2021","unstructured":"Mustapha R, Ng K, Monypenny J, Ng T. Insights into unveiling a potential role of tertiary lymphoid structures in metastasis. Front Mol Biosci. 2021;8:661516.","journal-title":"Front Mol Biosci"},{"key":"4196_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40164-025-00695-8","volume":"14","author":"M Radandish","year":"2025","unstructured":"Radandish M, Mashhadi N, Aghayan AH, et al. In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy. Exp Hematol Oncol. 2025;14:105.","journal-title":"Exp Hematol Oncol"},{"key":"4196_CR25","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/09273948.2019.1674891","volume":"29","author":"T Wang","year":"2021","unstructured":"Wang T, Li W, Cheng H, et al. The important role of the chemokine axis CCR7-CCL19 and CCR7-CCL21 in the pathophysiology of the Immuno-inflammatory response in dry eye disease. Ocul Immunol Inflamm. 2021;29:266\u201377.","journal-title":"Ocul Immunol Inflamm"},{"key":"4196_CR26","doi-asserted-by":"crossref","unstructured":"Purvanov V, Matti C, Samson GPB et al. Fluorescently tagged CCL19 and CCL21 to monitor CCR7 and ACKR4 functions. Int J Mol Sci. 2018;19:3876.","DOI":"10.3390\/ijms19123876"},{"key":"4196_CR27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12967-025-06358-w","volume":"23","author":"W Wahafu","year":"2025","unstructured":"Wahafu W, Zhou Q, Yang X, et al. Spatial relationships and interactions of immune cell niches are linked to the pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy. J Transl Med. 2025;23:375.","journal-title":"J Transl Med"},{"key":"4196_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13046-025-03318-6","volume":"44","author":"Z Li","year":"2025","unstructured":"Li Z, Liu S, Liu D, et al. Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint Blockade. J Exp Clin Cancer Res. 2025;44:84.","journal-title":"J Exp Clin Cancer Res"},{"key":"4196_CR29","doi-asserted-by":"publisher","first-page":"1900635","DOI":"10.1080\/2162402X.2021.1900635","volume":"10","author":"JG A","year":"2021","unstructured":"A JG, Rajamanickam V, Bui C, et al. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Oncoimmunology. 2021;10:1900635.","journal-title":"Oncoimmunology"},{"key":"4196_CR30","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1038\/s41467-022-30860-0","volume":"13","author":"MY Kim","year":"2022","unstructured":"Kim MY, Jayasinghe R, Devenport JM, et al. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. Nat Commun. 2022;13:3296.","journal-title":"Nat Commun"},{"key":"4196_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36:346\u201351.","journal-title":"Nat Biotechnol"},{"key":"4196_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.imlet.2020.06.001","volume":"225","author":"W Alturaiki","year":"2020","unstructured":"Alturaiki W. The roles of B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) in allergic asthma. Immunol Lett. 2020;225:25\u201330.","journal-title":"Immunol Lett"},{"key":"4196_CR33","doi-asserted-by":"crossref","unstructured":"Kratzmeier C, Taheri M, Mei Z et al. Lung adenocarcinoma-derived IFN-\u03b3 promotes growth by modulating CD8\u2009+\u2009T cell production of CCR5 chemokines. J Clin Invest . 2025;135:e191070.","DOI":"10.1172\/JCI191070"},{"key":"4196_CR34","doi-asserted-by":"publisher","first-page":"101065","DOI":"10.1016\/j.neo.2024.101065","volume":"58","author":"M He","year":"2024","unstructured":"He M, Ao X, Yang Y, et al. Construction of self-driving anti-\u03b1FR CAR-engineered NK cells based on IFN-\u03b3 and TNF-\u03b1 synergistically induced high expression of CXCL10. Neoplasia. 2024;58:101065.","journal-title":"Neoplasia"},{"key":"4196_CR35","doi-asserted-by":"publisher","first-page":"e2250281","DOI":"10.1002\/eji.202250281","volume":"54","author":"H Liu","year":"2024","unstructured":"Liu H, Wang Y, Le Q, et al. The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment. Eur J Immunol. 2024;54:e2250281.","journal-title":"Eur J Immunol"},{"key":"4196_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nri1786","volume":"6","author":"F Aloisi","year":"2006","unstructured":"Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006;6:205\u201317.","journal-title":"Nat Rev Immunol"},{"key":"4196_CR37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/ni1330","volume":"7","author":"DL Drayton","year":"2006","unstructured":"Drayton DL, Liao S, Mounzer RH, et al. Lymphoid organ development: from ontogeny to neogenesis. Nat Immunol. 2006;7:344\u201353.","journal-title":"Nat Immunol"},{"key":"4196_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561\u20135.","journal-title":"Nature"},{"key":"4196_CR39","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355.","journal-title":"Nature"},{"key":"4196_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"4196_CR41","doi-asserted-by":"publisher","first-page":"1049884","DOI":"10.3389\/fimmu.2022.1049884","volume":"13","author":"Y An","year":"2022","unstructured":"An Y, Sun JX, Xu MY, et al. Tertiary lymphoid structure patterns aid in identification of tumor microenvironment infiltration and selection of therapeutic agents in bladder cancer. Front Immunol. 2022;13:1049884.","journal-title":"Front Immunol"},{"key":"4196_CR42","doi-asserted-by":"publisher","first-page":"793992","DOI":"10.3389\/fimmu.2021.793992","volume":"12","author":"F Pagliarulo","year":"2021","unstructured":"Pagliarulo F, Cheng PF, Brugger L, et al. Molecular, Immunological, and clinical features associated with lymphoid neogenesis in muscle invasive bladder cancer. Front Immunol. 2021;12:793992.","journal-title":"Front Immunol"},{"key":"4196_CR43","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1158\/2326-6066.CIR-17-0716","volume":"6","author":"J Ma","year":"2018","unstructured":"Ma J, Wei K, Zhang H, et al. Mechanisms by which dendritic cells present tumor microparticle antigens to CD8(+) T cells. Cancer Immunol Res. 2018;6:1057\u201368.","journal-title":"Cancer Immunol Res"},{"key":"4196_CR44","doi-asserted-by":"crossref","unstructured":"Lanitis E, Irving M, Coukos G. Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy. Nat Rev Immunol. 2025;25:831\u2013846.","DOI":"10.1038\/s41577-025-01187-w"},{"key":"4196_CR45","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1038\/s41467-025-58958-1","volume":"16","author":"S Tang","year":"2025","unstructured":"Tang S, Che X, Wang J, et al. T-bet(+)CD8(+) T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers. Nat Commun. 2025;16:3905.","journal-title":"Nat Commun"},{"key":"4196_CR46","doi-asserted-by":"crossref","unstructured":"Chimote AA, Balajthy A, Arnold MJ et al. A defect in KCa3.1 channel activity limits the ability of CD8(+) T cells from cancer patients to infiltrate an adenosine-rich microenvironment. Sci Signal. 2018;11:eaaq1616.","DOI":"10.1126\/scisignal.aaq1616"},{"key":"4196_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.yexcr.2017.09.039","volume":"361","author":"M Bai","year":"2017","unstructured":"Bai M, Zheng Y, Liu H, et al. CXCR5(+) CD8(+) T cells potently infiltrate pancreatic tumors and present high functionality. Exp Cell Res. 2017;361:39\u201345.","journal-title":"Exp Cell Res"},{"key":"4196_CR48","doi-asserted-by":"publisher","first-page":"1267654","DOI":"10.3389\/fimmu.2023.1267654","volume":"14","author":"S Khanal","year":"2023","unstructured":"Khanal S, Wieland A, Gunderson AJ. Mechanisms of tertiary lymphoid structure formation: Cooperation between inflammation and antigenicity. Front Immunol. 2023;14:1267654.","journal-title":"Front Immunol"},{"key":"4196_CR49","doi-asserted-by":"publisher","first-page":"189312","DOI":"10.1016\/j.bbcan.2025.189312","volume":"1880","author":"M Cui","year":"2025","unstructured":"Cui M, Zhou M, Zhou L, et al. Tertiary lymphoid structures achieve \u2018cold\u2019 to \u2018hot\u2019 transition by remodeling the cold tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2025;1880:189312.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"4196_CR50","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/cas.14888","volume":"112","author":"T Mori","year":"2021","unstructured":"Mori T, Tanaka H, Suzuki S, et al. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer. Cancer Sci. 2021;112:1746\u201357.","journal-title":"Cancer Sci"},{"key":"4196_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00262-018-2259-0","volume":"68","author":"AM Weinstein","year":"2019","unstructured":"Weinstein AM, Giraldo NA, Petitprez F, et al. Association of IL-36\u03b3 with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunol Immunother. 2019;68:109\u201320.","journal-title":"Cancer Immunol Immunother"},{"key":"4196_CR52","doi-asserted-by":"publisher","first-page":"e70047","DOI":"10.1111\/imr.70047","volume":"332","author":"JJ Goronzy","year":"2025","unstructured":"Goronzy JJ, Weyand CM. Perivascular tertiary lymphoid structures in autoimmune disease. Immunol Rev. 2025;332:e70047.","journal-title":"Immunol Rev"},{"key":"4196_CR53","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.3389\/fimmu.2018.01214","volume":"9","author":"S Takamura","year":"2018","unstructured":"Takamura S. Niches for the Long-Term maintenance of Tissue-Resident memory T cells. Front Immunol. 2018;9:1214.","journal-title":"Front Immunol"},{"key":"4196_CR54","doi-asserted-by":"publisher","first-page":"1473969","DOI":"10.3389\/fimmu.2025.1473969","volume":"16","author":"A Varghese","year":"2025","unstructured":"Varghese A, Hess SM, Chilakapati S, et al. Exploring opportunities to improve immunotherapy in ovarian cancer. Front Immunol. 2025;16:1473969.","journal-title":"Front Immunol"},{"key":"4196_CR55","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1093\/oncolo\/oyad283","volume":"29","author":"G Ma","year":"2024","unstructured":"Ma G, Jia H, Zhang G, et al. Presence, Subtypes, and prognostic significance of tertiary lymphoid structures in urothelial carcinoma of the bladder. Oncologist. 2024;29:e248\u201358.","journal-title":"Oncologist"},{"key":"4196_CR56","doi-asserted-by":"crossref","unstructured":"Yilmaz F, Sagir S. Prognostic and predictive value of tertiary lymphoid structures in TURBT materials: Should it be seated in the routine pathological examination, and can it be used in deciding on the treatment method? Urol Oncol 2024; 42:450.e413-450.e422.","DOI":"10.1016\/j.urolonc.2024.06.010"},{"key":"4196_CR57","doi-asserted-by":"publisher","first-page":"1414884","DOI":"10.3389\/fimmu.2024.1414884","volume":"15","author":"B Jiang","year":"2024","unstructured":"Jiang B, Wu Z, Zhang Y, et al. Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis. Front Immunol. 2024;15:1414884.","journal-title":"Front Immunol"},{"key":"4196_CR58","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1002\/mc.70033","volume":"64","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yu G, Zheng Z, et al. IGHA1 and IGHG1 expression panel predicts Anti-PD-L1 response in Muscle-Invasive bladder cancer. Mol Carcinog. 2025;64:1942\u201355.","journal-title":"Mol Carcinog"},{"key":"4196_CR59","doi-asserted-by":"publisher","first-page":"793964","DOI":"10.3389\/fimmu.2021.793964","volume":"12","author":"N van Dijk","year":"2021","unstructured":"van Dijk N, Gil-Jimenez A, Silina K, et al. The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer. Front Immunol. 2021;12:793964.","journal-title":"Front Immunol"},{"key":"4196_CR60","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1016\/S1470-2045(24)00075-5","volume":"25","author":"C Lynch","year":"2024","unstructured":"Lynch C, Pitroda SP, Weichselbaum RR. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024;25:e352\u201362.","journal-title":"Lancet Oncol"},{"key":"4196_CR61","doi-asserted-by":"publisher","first-page":"122795","DOI":"10.1016\/j.biomaterials.2024.122795","volume":"313","author":"J Shen","year":"2025","unstructured":"Shen J, Feng K, Yu J, et al. Responsive and traceless assembly of iron nanoparticles and (131)I labeled radiopharmaceuticals for ferroptosis enhanced radio-immunotherapy. Biomaterials. 2025;313:122795.","journal-title":"Biomaterials"},{"key":"4196_CR62","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1021\/acs.molpharmaceut.8b00579","volume":"15","author":"MA Collier","year":"2018","unstructured":"Collier MA, Junkins RD, Gallovic MD, et al. Acetalated dextran microparticles for codelivery of STING and TLR7\/8 agonists. Mol Pharm. 2018;15:4933\u201346.","journal-title":"Mol Pharm"},{"key":"4196_CR63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41541-024-00869-1","volume":"9","author":"BC Gilmour","year":"2024","unstructured":"Gilmour BC, Corthay A, \u00d8ynebr\u00e5ten I. High production of IL-12 by human dendritic cells stimulated with combinations of pattern-recognition receptor agonists. NPJ Vaccines. 2024;9:83.","journal-title":"NPJ Vaccines"},{"key":"4196_CR64","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","volume":"25","author":"S Rivera-Orellana","year":"2025","unstructured":"Rivera-Orellana S, Bautista J, Palacios-Zavala D, et al. Oncolytic virotherapy and tumor microenvironment modulation. Clin Exp Med. 2025;25:256.","journal-title":"Clin Exp Med"},{"key":"4196_CR65","doi-asserted-by":"publisher","first-page":"e70978","DOI":"10.1002\/cam4.70978","volume":"14","author":"X Teng","year":"2025","unstructured":"Teng X, Chen Z, Bai Y, et al. Tertiary lymphoid structures as independent predictors of favorable prognosis in Muscle-Invasive bladder cancer. Cancer Med. 2025;14:e70978.","journal-title":"Cancer Med"},{"key":"4196_CR66","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y, et al. A consensus molecular classification of Muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"4196_CR67","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577:556\u201360.","journal-title":"Nature"},{"key":"4196_CR68","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/2159-8290.CD-21-0683","volume":"12","author":"V Kumar","year":"2022","unstructured":"Kumar V, Ramnarayanan K, Sundar R, et al. Single-Cell atlas of lineage States, tumor Microenvironment, and Subtype-Specific expression programs in gastric cancer. Cancer Discov. 2022;12:670\u201391.","journal-title":"Cancer Discov"},{"key":"4196_CR69","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10787-020-00762-y","volume":"28","author":"A Hejrati","year":"2020","unstructured":"Hejrati A, Rafiei A, Soltanshahi M, et al. Innate immune response in systemic autoimmune diseases: a potential target of therapy. Inflammopharmacology. 2020;28:1421\u201338.","journal-title":"Inflammopharmacology"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04196-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:02:53Z","timestamp":1770840173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04196-8","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}